Drugs / BC Combo THDB0207
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05373212 | May 2022 → Jan 2023 | type 2 diabetes mellitus | Adocia | Completed | No outcome recorded |
| Phase 1 | NCT05373199 | May → Oct 2022 | type 1 diabetes mellitus | Adocia | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC Combo THDB0207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05373212 ↗ |
| Route | Subcutaneous | “administered single subcutaneous doses of BC Combo THDB0207, Lantus®, and Humalog® at three separate dosing visits” NCT05373199 ↗ |